Prophylaxis use among males with haemophilia B in the United States
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Prophylaxis use among males with haemophilia B in the United States

Filetype[PDF-229.97 KB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Alternative Title:
      Haemophilia
    • Personal Author:
    • Description:
      Introduction

      Prophylaxis is considered the optimal treatment for persons with moderate to severe haemophilia (factor activity between 1–5% of normal and <1% of normal respectively) in countries where safe factor concentrates are available and economically feasible. Historically, prophylactic treatment has not been well studied in the haemophilia B (HB) population due to difficulties in obtaining a sufficiently large sample.

      Aim

      This study examines the prevalence of prophylaxis use among a robust sample of persons with HB in the United States and its association with specific demographic and clinical characteristics.

      Methods

      Using data collected between 1998 and 2011 for the Centers for Disease Control and Prevention’s Universal Data Collection project, we analysed data on 2428 males with moderate to severe HB aged 2–79 years who were seen at 135 federally funded haemophilia treatment centres.

      Results

      Prevalence of prophylactic treatment in our sample was 35% among children and youth (ages 2–19) and 14% among adults (age 20 and older). Increased HB prophylaxis use was significantly associated with younger age (<40 years), Hispanic ethnicity, severe disease and self-infusion, while decreased use was associated with above-normal body mass index (BMI) in adults. Health care coverage was vital, although type of coverage did not appear to influence access.

      Conclusions

      Our analysis confirms previous reports of lower prevalence of prophylaxis use among individuals with HB compared to those with haemophilia A and adds to the body of knowledge regarding treatment patterns among a historically understudied population.

    • Subjects:
    • Source:
      Haemophilia. 23(6):910-917.
    • Pubmed ID:
      28780772
    • Pubmed Central ID:
      PMC5724962
    • Document Type:
      Journal Article
    • Funding:
      CC999999/Intramural CDC HHS/United States
    • Name as Subject:
      Centers for Disease Control and Prevention (U.S.)
    • Place as Subject:
      United States
    • Collection(s):
    • Main Document Checksum:
    • Download URL:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov